AbbVie showcased 18 abstracts at the 2026 Digestive Disease Week, highlighting real-world and clinical trial data for its gastroenterology drugs risankizumab (SKYRIZI) and upadacitinib (RINVOQ) in treating Crohn's disease and ulcerative colitis. The data demonstrated sustained symptom relief, improved quality of life, and lower hospitalization rates, reinforcing the drugs' efficacy, safety, and durability. Notably, risankizumab showed low treatment switch rates, and upadacitinib reduced hospitalizations compared to biologic dose escalation. These findings support AbbVie's leadership in advancing inflammatory bowel disease care and may influence future treatment guidelines and approvals.
SKYRIZI achieved blockbuster sales of $11.7 billion in 2024, growing 51% year-over-year, driven by approvals in psoriasis, psoriatic arthritis, and inflammatory bowel diseases like Crohn's. Its strong clinical efficacy targeting the IL-23 pathway and...
In June, biotech stocks propelled the ALPS Medical Breakthroughs ETF (SBIO) to an 18.7% return, its best month since December 2023. Major contributors included Apogee Therapeutics, which surged 61.6% following a $10.9 billion acquisition announcement...
AbbVie is acquiring Apogee Therapeutics for $10.9 billion to strengthen its immunology portfolio and prepare for upcoming patent expirations. AbbVie's existing drugs Skyrizi and Rinvoq have already surpassed Humira's peak sales and continue growing r...
In June 2026, biotechnology ETFs dominated the top performers, driven by AI advancements and increased mergers and acquisitions, with ARKG leading at a 24.15% return. Passive biotech ETFs like BBC, SBIO, and XBI also saw strong gains. Meanwhile, the ...
